stoxline Quote Chart Rank Option Currency Glossary
  
CorMedix Inc. (CRMD)
5.28  -0.14 (-2.58%)    04-19 16:00
Open: 5.5
High: 6.22
Volume: 1,949,116
  
Pre. Close: 5.42
Low: 5.13
Market Cap: 289(M)
Technical analysis
2024-04-19 5:08:39 PM
Short term     
Mid term     
Targets 6-month :  8.04 1-year :  9.39
Resists First :  6.88 Second :  8.04
Pivot price 5.03
Supports First :  4.88 Second :  3.64
MAs MA(5) :  5.38 MA(20) :  4.8
MA(100) :  3.71 MA(250) :  3.97
MACD MACD :  0.4 Signal :  0.4
%K %D K(14,3) :  46.8 D(3) :  47.9
RSI RSI(14): 60.9
52-week High :  6.88 Low :  2.56
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CRMD ] has closed below upper band by 40.4%. Bollinger Bands are 201.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 6.22 - 6.26 6.26 - 6.3
Low: 5.06 - 5.1 5.1 - 5.13
Close: 5.23 - 5.29 5.29 - 5.33
Company Description

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Headline News

Mon, 08 Apr 2024
CorMedix (CRMD) Shows Strength: Stock Moves Up 35.8% - Yahoo Movies UK

Sat, 06 Apr 2024
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth - Simply Wall St

Tue, 02 Apr 2024
Breakeven On The Horizon For CorMedix Inc. (NASDAQ:CRMD) - Yahoo Finance

Wed, 13 Mar 2024
Earnings call: CorMedix outlines DefenCath launch and financials - Investing.com

Wed, 13 Mar 2024
Cormedix Inc.'s DefenCath Success Hinges on Two Major Dialysis Providers: A High-Stakes Gamble in Outpatient ... - TipRanks

Tue, 12 Mar 2024
CorMedix: Q4 Earnings Snapshot - Houston Chronicle

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 55 (M)
Shares Float 54 (M)
Held by Insiders 1 (%)
Held by Institutions 34.1 (%)
Shares Short 8,250 (K)
Shares Short P.Month 7,720 (K)
Stock Financials
EPS -0.92
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.27
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -42.5 %
Return on Equity (ttm) -74.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -0.89
Qtrly Earnings Growth 0 %
Operating Cash Flow -38 (M)
Levered Free Cash Flow -23 (M)
Stock Valuations
PE Ratio -5.81
PEG Ratio 0
Price to Book value 4.12
Price to Sales 0
Price to Cash Flow -7.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android